Afe Babalola Bemoans Scientists’ Inability To Translate Research To Products

Afe Babalola

The Founder, Afe Babalola University, Ado Ekiti, Aare Afe Babalola (SAN), on Monday lamented Nigerian scientists’ inability to translate their research into products within the shortest time possible.

Babalola bemoaned that year after, the clinical trial of ABUAD Herbal Virucidine Liquid, which was produced by the university’s scientists at the peak of COVID-19, was yet to be completed due to the Nigerian system’s inefficiency.

The ABUAD founder, who spoke at the university during the opening of the Drug Discovery Africa 2022 Conference with the theme, ‘Evolving lead compounds from nature,’ harped on the need for appropriate authorities to remove the clogs in the wheels of making scientists’ efforts come to fruition in no time.

He said, “I appeal to this body, to ensure that this bureaucratic bottleneck is immediately removed to ensure that scientists can translate their researches into products in the shortest time possible as done in other climes where within five months, they were able to produce drugs/vaccines for COVID-19”.

Babalola said that ABUAD had succeeded in developing ABUAD Herbal Virucidine Liquid which has been registered by the National Agency for Food Administration and Control as an immune booster and anti-oxidant and was currently undergoing clinical trial for COVID-19 treatment.

“As a matter of fact, I can tell you that the Nigerian Institute of Medical Research, Federal Medical Centre, Ebute Metta, Mainland Hospital, Lagos, and the hospitals in Ekiti have confirmed 72 hours of zero-conversion in COVID-19 patients.

“The bio-medical research on Virucidine was completed at the peak of COVID-19 and approval was granted nine months later. Unfortunately, up till now, despite spending millions of naira, the clinical trial is yet to be completed due to system inefficiency,” Babalola said.


(Visited 78 times, 1 visits today)